A little light blog keeping to do today. If you haven’t listened to one of the podcasts, the podcast archive is now up and running. If you have yet to subscribe to the podcast feed – you can go here – and grab the link. The media page is now up as well, so you can go have a look at what’s been written about the Health Care Blog recently.
POLICY: Employment-based healthcare, more of the same uneven erosion
There are two ways employers get out of providing health care. They can stop providing it (and plenty of data shows that they are doing just that) and they can also pass more of the cost onto their employees. That also has the impact that at the margin their employees stop purchasing it for their families or themselves. But it has one more impact, which is that the employees’ costs are going up much faster than the employers.
California Healthline had a good summary of a WSJ article and other accounts of a Mercer survey this week showing that pushing more costs onto workers reduces the employers’ costs (or at least reduces the amount of increase in those costs).
According to the survey, employers’ health care costs rose 6.1% in 2005, compared with 7.5% in 2004, 10.1% in 2003 and 14.7% in 2002. The average cost of company health plans increased from $6,679 per employee in 2004 to $7,089 per employee in 2005, the survey found . Employer spending on health coverage would have increased 10% in 2005 without the shift in cost to employees and changes to health plans, according to the survey.
Now there’s nothing revelatory here, other than some continued misunderstanding by economists that this is just moving the deckchairs on the Titanic. It is moving the deck chairs on the Titanic in terms of containing overall health costs–they’re not going to be much affected by who ends up picking up the tab at the margins. But despite the feelings of snooty doctoral students at Harvard and even brilliant health economists at Stanford, there is an impact in the real world from who pays for what.
That’s because it’s not as if employers are rewarding their employees with extra cash to replace essentially lowering their health care benefits (or making them pay higher "premium per benefit"). So those employers who cut benefits more have lower labor costs and therefore make higher profits. Hence the continued difference in the margins of Costco and unionized supermarkets on the one hand and the Wal-Mart on the other. This leads to those economists who’ve vacated the Ivory Towers and instead taken the lure of the filthy lucre to become analysts on Wall Street to put continued pressure on the "good" companies to end up looking like the Wal-Marts of the world. Which has been playing out in labor disputes across the country and even has affected the hallowed halls of General Motors itself.
And while the end of the employer-based health care system is something I am in favor of, I’m not in favor of it dying by a thousand cuts while nothing is there to replace it.
Coda: The crack at the Harvard doctoral student is an old chestnut here at THCB. However, me taking aim at America’s greatest health economist and my old professor Vic Fuchs is quite another thing. Here’s what he said in his latest Health Affairs article, which (apart from this little dispute is excellent as you’d expect):
Today the largest private employer is Wal-Mart, which despite its size faces intense competition daily from a host of other retail outlets. When they offer health insurance, it must come out of their workers’ wages; for minimum-wage employees, this is not possible, so it often will mean loss of jobs.
While that is true across the economy, it assumes that there are constant margins among firms within one industry. But we know that’s not true. Wal-Mart has much higher margins and higher profits than other retailers. it could easily afford more generous health benefits, and maybe would have them if it was unionized. However, we know that Wal-Mart spends incredible amounts of effort to prevent unions getting a foothold, partly because of the health insurance issue, and overall in order to keep its labor costs lower. Wal-Mart tries to keep all of its costs lower including those of its suppliers, other than one set of "costs" — those that it retains as earnings, some of which it pays to its shareholders. So to say that "It must come out of their wages" only really holds true if you count the dividends that the Walton family (net worth >$100 billion) collects as "wages". You could just pay them (and the other shareholders) lower margins and pay the workers more in health benefits. That’s exactly what Costco does. But that’s the real world not the economists’ theoretical level playing field that Vic Fuchs doesn’t usually get stuck on.
Technorati: healthcare, health, insurance, policy, politics, economics, medicare, news and politics
Policy: What is a transplant worth? By John Pluenneke
Nearly a hundred thousand Americans are on waiting lists hoping for organ transplants. Thousands will
die this year alone. Should a free market be allowed to develop to allow those who
can afford to do so to purchase the liver or kidney that will let them to go on
living?
Rather surprisingly, I find
myself agreeing with an editorial in the San Francisco Chronicle today by David
Holcberg at the Ayn Rand Institute – of all places – who argues that opponents of a legalized
organ trade, although well-intentioned, have it the wrong way around.
Poor people, they claim, are
incapable of making rational choices, and so must be protected from themselves.
But the fact is that human beings (poor or rich) do have the capacity of reason
and should be free to exercise it. Of course, the decision to sell an organ
should not be made lightly. That some people might make irrational choices,
however, is no reason to violate the rights of everyone. If the law recognizes
our right to give away an organ, it should also recognize our right to sell one.
There are important questions which Holcberg
does not address. What would such a market look
like? How would it be regulated, if at
all? Who among us is to say what the
exact price of a heart should be? A million
dollars? Two? What about a kidney?
The implications
for society as a whole are thought-provoking. The skeptics are
correct of course when they raise questions. Would there be instances in which desperately
ill people were taken advantage of by the greedy and unscrupulous? Clearly, yes. But then again, that already happens every
day. It’s time for a sane policy.
UPDATE: The compensation issue is clearly going to get a lot of play after the latest developments in the ethics controversy surrounding the Korean stem cell program. Last week, there was the news that Korean researchers paid women the equivalent of $1,500 each to donate their eggs to help scientist Dr. Hwang Woo Suk’s research. Then, last night Korean TV broadcast an hour long special in which several women who took part in the experiments say they were under financial pressure at the time. Roh Sung Il, the manager of the Seoul fertility clinic involved, argues the arrangement was not outlawed at the time the donations took place …
The latest evidence appears to show that Koreans still back Hwang – who is considered a national hero for his work. The Korea Times has a poll out this morning that claims 2 out of 3 Koreans still support Hwang despite the charges.
Technorati: healthcare, health, insurance, policy, politics, economics, medicare, news and politics, stem cell research
PHARMA: Pain Therapeutics causes yet more headaches
Those of you hanging out here for a while know that I’m a long term holder of Pain Therapeutics stock. The pitch is that it has three drugs in phase III trials, one for pain, one for IBS and one a non-alterable version of Oxycontin. the stock went public at 14, it usually trades between 6 and 9, and I bought a boatload at between 2 & 4 in the dark days of late 2002/early 2003.
Now I’ve been hanging on for the last of two phase III trials of its star drug Oxytrex, which is supposed to be a non-addictive version of Oxycodone (the active ingredient in Oxycontin which is a multi-billion $$ drug). The first Phase III trial looked good, but was a little inconclusive, and the stock that was hovering in the 5-6 range didn’t move much. Still given the company’s market cap is only in the low hundred millions and any one of these drugs alone if successful is worth several billions, it’s always looked a good bet to me.
Then last week Pain Therapeutics cut a great deal in which it essentially passed off a share of the profits and all of the costs for its third line drug Remoxy (yes the CEO’s name is "Remi"–no ego huh!), which is a non-alterable version of Oxycontin (and therefore can’t be abused as Oxycontin or "Hillbilly Heroin" is frequently), to King Pharma for up to $400m, including $150m in cash. The stock went up about $2.50 and I was looking forward to a conclusive phase III for Oxytrex leading to an FDA approval.
So today the Phase III results are out and they are maddening. The drug appears to work, but too many people dropped out of the trial, and so the results are not statistically significant. My guess is that the FDA will make them go around again. The stock is now back down to more or less where it was before the King deal (so I suppose it could have been a good deal worse). But still no clear end in sight.
I’ve been hanging on for about 3 years. And of course in the meantime I didn’t buy any Google stock because it didn’t have much upside….
Any suggestions from my readers as to what I should do now?
POLICY: CHCF report on Safety Net Clinics
Given that the community clinics are apparently our brave leader’s only thoughts about how to provide care for the poor in America, it’s pretty timely that a new California Health Care Foundation study is out giving a primer on safety net clinics in California (PDF). And of course the population they serve is often underserved, uninsured, doesn’t speak English, and is growing. Here’s the conclusion.
SAFETY-NET CLINICS HAVE BECOME INDISPENSABLE components of the health care system for vulnerable and underserved populations. However, these clinics rely on a patchwork of funding sources to provide comprehensive primary care and preventive services in the communities they serve. In the current operational climate these clinics face major challenges to longterm sustainability and expansion to meet the needs of growing numbers of uninsured
Note: I have worked recently for CHCF, and while as a Foundation it cannot take political stances or voice exact opinions, I can only applaud its efforts in shining a bright light into the murkier parts of our nation’s health care "policy"
PHARMA/POLICY/POLITICS: Medicare Part D–A mess that will need fixing when the grown-ups get back into power
Last week the most convoluted program in the history of Medicare began. I’ve heard comments from friends, neighbors and people in the press saying that they can’t make heads or tails of the new drug benefit. The Washington Post piled in on Saturday with yet more about how confused seniors are.
Whether you like it or loathe it, there are some interesting parts of the Medicare Modernization Act, including the HSA provision and the disease management provisions. But the main event–drug coverage–is neither rational nor ideologically consistent. It’s a dog’s breakfast put together to ensure that the PBMs and some private health plans have something extra to sell, and so that the pharmaceutical companies don’t have to deal directly with the government on pricing.
Now seniors are going to have to deal with a donut hole, out-of-pocket costs, in-network and out-of-network pharmacies, and deciding whether their employer-sponsored coverage is going to stay around. No wonder they’re confused.
And despite all this, the cost to taxpayers is going to be double what Congress was told it would be. Drug coverage for everyone (especially seniors) is needed. But the only prediction I can make is that a more fiscally and socially responsible government–should we get one–will be forced to re-sort this mess in the very near future.
Technorati: healthcare, health, insurance, policy, politics, economics, medicare, news and politics
TECH: The evolution of wireless in hospitals
Now that cell phones and Wi-fi have proven to be safe and essential for health care facilities, there’s a race on to get signals into those buildings. This is proving to have some interesting possibilities, but is also bringing some technical challenges to hospital technology managers. Frequently buildings are too dense to allow good cell phone signal, while increased demand for Wi-fi and VOIP is putting pressure on the ad-hoc Wi-fi networks being built up in many hospitals. One solution gaining traction is to locate PCS, cellular and paging, and Wi-fi services centrally and create a series of ceiling-based transmitters to amplify and distribute the various signals. One company in the forefront of this is InnerWireless, which has announced several installation wins in recent weeks. I recently spoke with Jim McCoy, chief technology officer of InnerWireless, and Tuomo Rutanen of Ekahau to find out a little more about what’s going on inside the wireless world for hospitals.
Wireless and Wi-fi are different. InnerWireless’ technology deploys Wi-fi, as well as PCS, cellular, 2 way radio, 2 way paging and other signals. Conventional practice for Wi-fi is to deploy those points throughout a floor or department. Innerwireless co locates those Wi-fi access points at one place per floor, combine their outputs and then injects them onto their distributed antenna, therefore giving every user the strength of multiple antenna to access. This enhances Wi-fi data and more importantly VOIP performance. There tend to be around 6 distributed antenna per typical 20,000 sq ft floor, each one up in a ceiling panel where it’s installed once and forgotten about. All other services (cellular, PCS, etc) are piped to the same access point from aggregated through a main console room. And of course once the central points are in for cellular, it’s probably more cost-effective to layer Wi-fi into that system than to do it with ad-hoc networks.
In addition InnerWireless, Ekahau, and others are developing the ability to track patients, products and equipment in a cost-effective real time manner using the Wi-fi network–an always-on alternative to RFID which works sort of like an “indoors GPS”. They are both deploying tracking tags on people and equipment, and the size and price of those tags is falling rapidly. Ekahau’s approach takes advantage of the existing Wi-fi network, whereas InnerWireless uses its installed antennas and adds several more battery-operated sensors (probably 20 more per floor) to extend the accuracy of its trackers. Innerwireless is running their tracking over a different system within their infrastructure and are using the 802.15.4 standard for the tags.
These are two innovative companies attacking a key problem for health care facilities. Given the problems hospitals have locating their staff, patients and other movable parts, expect this technology to spread rapidly.
FDA examining Oseltamivir risks by John Pluenneke
If you read FierceHealthcare, you had advance warning of this one on Monday. The Wall Street Journal reported yesterday afternoon that the Food and Drug Administration is probing as many as 12 deaths it believes may be linked to oseltamivir (i.e. Tamiflu) in Japan. According to the paper, all of the victims were children.
Quoting from the source:
The FDA said there were 32 reports of "neuropsychiatric" adverse events, 31 of which happened in Japan, and included abnormal behavior, hallucinations, convulsions and encephalitis. The agency said it received a report of two patients, ages 12 and 13, jumping out of their windows after receiving two doses of Tamiflu.
The antiviral, which is jointly distributed by Roche and Gilead Life Sciences, is considered the best available treatment for the H5N1 virus, although not everybody agrees it will work. Given the recent hype about the drug, this is a development worth watching closely. Apparently the FDA has known about these allegations for some time – as in for many months. Expect a lot of talk in the media about this story and its implications once it sinks in.
Also expect the story to take center stage in the fight in Washington over the liability protections vaccine makers and drug companies say they want …Update: On Friday, an FDA advisory panel said it could find no evidence linking Tamiflu with the deaths in Japan. Meanwhile, in response to public pressure, Japan’s independent Pharmaceuticals and Medical Devices agency said it will begin publishing detailed data on all reports of adverse events it recieves related to prescription drugs and medical devices starting in January 2006.
PHARMA/POLICY/INTERNATIONAL: Not all the wingnuts are in the US
Australia had some great news yesterday as the national team qualified for the soccer world cup, even though it’s only the 4th most popular team sport with the word "football" in the title in the country. But there was also some more bad news. The way that the national broadcaster ABC presented it as Australia’s rural doctors disappointed by Abbott’s abortion pill decision.
Abbott is not the drug company, it’s Tony Abbott the health minister. Because I randomly know his sister and parents, I can tell you that what’s not in the article is that Abbott is a devout Catholic who nearly became a priest. Meanwhile he’s been kicked around in the Australian press for kow-towing to the pharmacist lobby on pricing, and also for not forcing promised cuts in generic prices. He was also at the center of some more complex wrangling over drugs in the free trade pact that many on the left in Australia are very suspicious about, but where I felt they walked a tight-rope fairly well in getting the free-trade deal done.
But the reason given for the ban on RU-486 is that rural doctors wouldn’t be able to treat women using it. Well as evidenced from the statements by rural doctors managed just fine to treat women who spontaneously abort, that’s pure bunk. Which leads us to the conclusion that yet again religion and ideology have trumped science at the highest levels of national decisions about drugs.
POLICY: Yet more Dartmouth proof about doing too much
We’re almost at the point that you know exactly what any study from the Dartmouth group is going to find before it’s published. Following the assessment last year that showed that the nations “Top 100” hospitals show a wide variety of difference in procedures in their ICUs, for no apparent difference in outcomes, the same result comes up again. This time (with Stanford’s Lauren Baker playing a starring cameo) Wennberg, Fisher et al looked at Medicare spending on patients in the last two years of life in hospitals in California and once again geography is destiny. (Health Affairs article here)
The study found that reimbursements ranged from $19,745 per Medicare patient at Redwood Memorial Hospital in Humboldt County’s Fortuna to $88,661 at Garfield Medical Center in Monterey Park in the San Gabriel Valley
Sacramento was cheaper than the Bay Area which was in turn cheaper than Los Angeles. And of course the outcomes were similar in all places and had little relation to the costs. Interestingly, hospital chain is also a predictor. Sutter, which isn’t exactly known by California’s health plans as being a low cost operator, did way less than Tenet. (although I don’t know if Redding Medical Center skewed the data by itself!)
Medicare spending was also higher in some large hospital systems. Sutter Health, which operates 27 hospitals in Northern California, spent $30,814 on average per Medicare patient in the last two years of life, compared with $46,323 at Tenet Healthcare Corp.
Given that these are the most expensive patients (the 10% that cost 50% of all dollars), and moreover “it’s my money dammit”, you’d think that our so-called conservative leaders would be seizing on this to try to do something about the practice variation problem. But it just seems to be accepted as some type of unintelligent design.